Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
JCO Precis Oncol
; 8: e2300686, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38905574
ABSTRACT
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Receptor ErbB-2
/
Trastuzumab
/
Recidiva Local de Neoplasia
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article